Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > preliminary short form prospectus

<< Previous

Bullboard Posts

Next >>

Comment by spesestsemperon Jul 18, 2024 3:35pm

93 Views

Post# 36138944

RE:RE:preliminary short form prospectus

Thats good then - just came up . The clock is ticking for christophe to bring home the bacon . time is of the essence . I dont know about anyone else but my clock is almost done . If nobody is interested in the company in the next little bit - do they really have anything to sell ? I'm doubting roche is even in the picture except maybe as a supplier .

<< Previous

Bullboard Posts

Next >>

Online behaviour puts Canadians at risk of cyberattacks, study finds